scholarly journals Treatment of the novel COVID-19: why Costa Rica’s proposal for the creation of a global pooling mechanism deserves serious consideration?

2020 ◽  
Vol 7 (1) ◽  
Author(s):  
Muhammad Zaheer Abbas
Keyword(s):  
Point Of Care ◽  
World Health ◽  
Director General ◽  
Point Of Care Diagnostics ◽  
Travel Restrictions ◽  
Regulatory Data ◽  
Health Products ◽  
The Creation ◽  
Health Organization ◽  
Spread Of Infection

ABSTRACT The COVID-19 is causing not only deaths and fear but also economic and social harm across the globe. Lockdowns, travel restrictions, quarantines, social distancing, and other strict public health measures are playing their part in delaying the spread of infection, but a safe and potent vaccine, effective therapeutics, point-of-care diagnostics, and other health products are desperately needed because it may not be practically possible for governments to extend these measures for an indefinite period of time. On March 23, Costa Rica submitted a proposal to the Director-General of the World Health Organization for the creation of a global pooling mechanism in order to facilitate access to and use of intellectual property, trade-secret know-how, regulatory data, cell lines, product blueprints, and other proprietary data for technologies that are useful for the detection, prevention, control, and treatment of the COVID-19 pandemic. This study critically evaluates Costa Rica’s proposal and endeavors to briefly answer the following questions: Why Costa Rica’s proposal deserves serious consideration? To what extent this proposal addresses some of the key concerns related to the COVID-19? To what extent this proposal is practically feasible?

A short review on important drugs under clinical trial against Covid-19

2020 ◽  
Vol 21 ◽  
Author(s):  
Namita Misra
Keyword(s):  
Respiratory Illness ◽  
Short Review ◽  
World Health ◽  
Upper Respiratory Tract ◽  
Suspected Infection ◽  
Medicinal Treatment ◽  
Travel Restrictions ◽  
Personal Level ◽  
Health Organization ◽  
Tract Infections

: Corona virus spreads from one to other person, either by touching the hands or by touching the surface contaminated with this virus, and then touching the nose or mouth. Covid-19 infected human symptoms are like any pneumonia symptoms, dry cough and high fever. Upper respiratory tract infections symptoms and sore throat are rare. First notified in china dated 12th December 2019 as a respiratory illness. In addition to travel restrictions and quarantine measures everyone should follow the World Health Organization advice guidelines on the management of humans infected with known or suspected infection with SARS-CoV-2 virus at the personal level. The development of vaccine or medicines for the same are under progress and this short review will summarize the most potential candidates such as Remdesivir, Lopinavir and Ritonavir, Chloroquine, Hydroxychloroquine, Hydroxychloroquine with Azithromycin, Favipiravir, Umifenovir, and Ribavirin for its medicinal treatment.

viewpoint TIME TO RESTART: PROTOCOL OF RESUMPTION OF ACTIVITIES OF A DERMATOLOGICAL CLINIC OF A LEVEL II HOSPITAL IN THE COVID-19 ERA. (Preprint)

2020 ◽  
Author(s):  
Federico Diotallevi ◽  
Anna Campanati ◽  
Giulia Radi ◽  
Oriana Simonetti ◽  
Emanuela Martina ◽  
...  
Keyword(s):  
Healthcare Workers ◽  
World Health ◽  
New Wave ◽  
Staff Members ◽  
Level Ii ◽  
The World ◽  
Health Organization ◽  
Spread Of Infection ◽  
Hospital Wards ◽  
Medical And Healthcare

UNSTRUCTURED Two months have passed since the World Health Organization (WHO) declared the pandemic of the Coronavirus Disease 19 (COVID-19), caused by the SARS CoV-2 virus, on March 11, 2020. Medical and healthcare workers have continued to be on the frontline to defeat this disease, however, continual changes are being made to their working habits which are proving to be difficult. Since the beginning of the pandemic, a major reorganisation of all hospital wards, including dermatological wards, has been carried out in order to make medical and nursing staff available in COVID wards and to prevent the spread of infection. These strategies, which were also adopted in our clinic, proved to be effective, as no staff members or patients were infected by the virus. Now, thanks to the global decrease in SARS-CovV2 infections, it is necessary to make dermatological wards accessible to patients again, but it is also essential to adopt specific protocols to avoid a new wave of infections.

ARIMA model for forecasting COVID-19 Death cases in India (Preprint)

2020 ◽  
Author(s):  
Jeya Sutha M
Keyword(s):  
Arima Model ◽  
Public Health Emergency ◽  
World Health ◽  
The People ◽  
The World ◽  
The Status ◽  
The Government ◽  
Health Organization ◽  
Spread Of Infection ◽  
Death Cases

UNSTRUCTURED COVID-19, the disease caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a highly contagious disease. On January 30, 2020 the World Health Organization declared the outbreak as a Public Health Emergency of International Concern. As of July 25, 2020; 15,947,292 laboratory-confirmed and 642,814 deaths have been reported globally. India has reported 1,338,928 confirmed cases and 31,412 deaths till date. This paper presents different aspects of COVID-19, visualization of the spread of infection and presents the ARIMA model for forecasting the status of COVID-19 death cases in the next 50 days in order to take necessary precaution by the Government to save the people.

scholarly journals A 3D-printed magnetic digital microfluidic diagnostic platform for rapid colorimetric sensing of carbapenemase-producing Enterobacteriaceae

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Pojchanun Kanitthamniyom ◽  
Pei Yun Hon ◽  
Aiwu Zhou ◽  
Mohammad Yazid Abdad ◽  
Zhi Yun Leow ◽  
...  
Keyword(s):  
Point Of Care ◽  
Resistance Mechanism ◽  
Turnaround Time ◽  
World Health ◽  
Colorimetric Sensing ◽  
Resource Limited ◽  
Reaction Chambers ◽  
Technological Platform ◽  
Health Organization ◽  
Digital Microfluidic

AbstractCarbapenemase-producing Enterobacteriaceae (CPE) are a group of drug-resistant Gram-negative pathogens that are classified as a critical threat by the World Health Organization (WHO). Conventional methods of detecting antibiotic-resistant pathogens do not assess the resistance mechanism and are often time-consuming and laborious. We have developed a magnetic digital microfluidic (MDM) platform, known as MDM Carba, for the identification of CPE by measuring their ability to hydrolyze carbapenem antibiotics. MDM Carba offers the ability to rapidly test CPE and reduce the amount of reagents used compared with conventional phenotypic testing. On the MDM Carba platform, tests are performed in droplets that function as reaction chambers, and fluidic operations are accomplished by manipulating these droplets with magnetic force. The simple droplet-based magnetic fluidic operation allows easy system automation and simplified hands-on operation. Because of the unique “power-free” operation of MDM technology, the MDM Carba platform can also be operated manually, showing great potential for point-of-care testing in resource-limited settings. We tested 27 bacterial isolates on the MDM Carba platform, and the results showed sensitivity and specificity that were comparable to those of the widely used Carba NP test. MDM Carba may shorten the overall turnaround time for CPE identification, thereby enabling more timely clinical decisions for better clinical outcomes. MDM Carba is a technological platform that can be further developed to improve diagnostics for other types of antibiotic resistance with minor modifications.

scholarly journals Countries with delayed COVID-19 introduction – characteristics, drivers, gaps, and opportunities

2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Zheng Li ◽  
Cynthia Jones ◽  
Girum S. Ejigu ◽  
Nisha George ◽  
Amanda L. Geller ◽  
...  
Keyword(s):  
Geographic Location ◽  
Control Measures ◽  
World Health ◽  
Small Island ◽  
Influenza Surveillance ◽  
Middle Income ◽  
School Closing ◽  
Travel Restrictions ◽  
Potential Factors ◽  
Health Organization

Abstract Background Three months after the first reported cases, COVID-19 had spread to nearly 90% of World Health Organization (WHO) member states and only 24 countries had not reported cases as of 30 March 2020. This analysis aimed to 1) assess characteristics, capability to detect and monitor COVID-19, and disease control measures in these 24 countries, 2) understand potential factors for the reported delayed COVID-19 introduction, and 3) identify gaps and opportunities for outbreak preparedness, particularly in low and middle-income countries (LMICs). We collected and analyzed publicly available information on country characteristics, COVID-19 testing, influenza surveillance, border measures, and preparedness activities in these countries. We also assessed the association between the temporal spread of COVID-19 in all countries with reported cases with globalization indicator and geographic location. Results Temporal spreading of COVID-19 was strongly associated with countries’ globalization indicator and geographic location. Most of the 24 countries with delayed COVID-19 introduction were LMICs; 88% were small island or landlocked developing countries. As of 30 March 2020, only 38% of these countries reported in-country COVID-19 testing capability, and 71% reported conducting influenza surveillance during the past year. All had implemented two or more border measures, (e.g., travel restrictions and border closures) and multiple preparedness activities (e.g., national preparedness plans and school closing). Conclusions Limited testing capacity suggests that most of the 24 delayed countries may have lacked the capability to detect and identify cases early through sentinel and case-based surveillance. Low global connectedness, geographic isolation, and border measures were common among these countries and may have contributed to the delayed introduction of COVID-19 into these countries. This paper contributes to identifying opportunities for pandemic preparedness, such as increasing disease detection, surveillance, and international collaborations. As the global situation continues to evolve, it is essential for countries to improve and prioritize their capacities to rapidly prevent, detect, and respond, not only for COVID-19, but also for future outbreaks.

scholarly journals Scientific Certainty in a Time of Uncertainty: Predicting Vulnerability of Canada's First Nations to Pandemic H1N1/09

2010 ◽  
Vol 1 (1) ◽  
Author(s):  
Nicholas Spence ◽  
Jerry P. White
Keyword(s):  
World Health Organization ◽  
First Nations ◽  
Influenza Pandemic ◽  
Scientific Evidence ◽  
Indigenous Populations ◽  
World Health ◽  
Director General ◽  
Pandemic H1n1 ◽  
The World ◽  
Health Organization

On June 11, 2009, the Director General of the World Health Organization, Dr. Margaret Chan, announced that the scientific evidence indicated that the criteria for an influenza pandemic had been met: pandemic H1N1/09 virus, the first in nearly 40 years, was officially upon us. The World Health Organization has estimated that as many as 2 billion or between 15 and 45 percent of the population globally will be infected by the H1N1/09 virus. Scientists and governments have been careful to walk a line between causing mass public fear and ensuring people take the risks seriously. The latest information indicates that the majority of individuals infected with the H1N1/09 virus thus far have suffered mild illness, although very severe and fatal illness have been observed in a small number of cases, even in young and healthy people (World Health Organization 2009c). There is no evidence to date that the virus has mutated to a more virulent or lethal form; however, as we enter the second wave of the pandemic, a significant number of people in countries across the world are susceptible to infection. Most importantly, certain subgroups have been categorized as high risk given the clinical evidence to date. One of these subgroups is Indigenous populations (World Health Organization 2009c).

Developing Medicines in Line with Global Public Health Needs: The Role of the World Health Organization

2011 ◽  
Vol 20 (2) ◽  
pp. 290-297 ◽  
Author(s):  
TIKKI PANG
Keyword(s):  
World Health Organization ◽  
Gender Violence ◽  
Sub Saharan Africa ◽  
World Health ◽  
Director General ◽  
Global Public Health ◽  
Absolute Poverty ◽  
The World ◽  
Health Organization ◽  
The Impact

“I want my leadership to be judged by the impact of our work on the health of two populations: women and the people of Africa.” This is how Dr. Margaret Chan, the current Director-General of the World Health Organization (WHO), described her leadership mission. The reason behind this mission is evident. Women and girls constitute 70% of the world’s poor and 80% of the world’s refugees. Gender violence against women aged 15–44 is responsible for more deaths and disability than cancer, malaria, traffic accidents, and war. An estimated 350,000 to 500,000 women still die in childbirth every year. The negative health implications of absolute poverty are worst in Sub-Saharan Africa and South Asia. Hence, Chan aims to have the biggest impact on the world’s poorest people.

The Reaction to the Ebola Epidemic within the United Nations Framework: What Next for the World Health Organization?

2014 ◽  
Vol 18 (1) ◽  
pp. 405-424
Author(s):  
Pia Acconci
Keyword(s):  
United Nations ◽  
World Health Organization ◽  
Security Council ◽  
International Health ◽  
World Health ◽  
Director General ◽  
The World ◽  
The United Nations ◽  
Health Organization

The World Health Organization (who) was established in 1946 as a specialized agency of the United Nations (un). Since its establishment, the who has managed outbreaks of infectious diseases from a regulatory, as well as an operational perspective. The adoption of the International Health Regulations (ihrs) has been an important achievement from the former perspective. When the Ebola epidemic intensified in 2014, the who Director General issued temporary recommendations under the ihrs in order to reduce the spread of the disease and minimize cross-border barriers to international trade. The un Secretary General and then the Security Council and the General Assembly have also taken action against the Ebola epidemic. In particular, the Security Council adopted a resolution under Chapter vii of the un Charter, and thus connected the maintenance of the international peace and security to the health and social emergency. After dealing with the role of the who as a guide and coordinator of the reaction to epidemics, this article shows how the action by the Security Council against the Ebola epidemic impacts on the who ‘authority’ for the protection of health.

scholarly journals COVID-19: Current Developments and Further Opportunities in Drug Delivery and Therapeutics

Pharmaceutics ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 945
Author(s):  
Saman Zafar ◽  
Muhammad Sohail Arshad ◽  
Sameen Fatima ◽  
Amna Ali ◽  
Aliyah Zaman ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Vaccine Development ◽  
Viral Vector ◽  
Age Groups ◽  
World Health ◽  
Disease Spread ◽  
Plasma Therapy ◽  
Antiviral Therapies ◽  
Health Organization ◽  
Spread Of Infection

SARS-CoV-2 has affected people from all age groups, races and ethnicities. Given that many infected individuals are asymptomatic, they transmit the disease to others unknowingly, which has resulted in the spread of infection at an alarming rate. This review aims to provide an overview of the pathophysiology, preventive measures to reduce the disease spread, therapies currently in use, an update on vaccine development and opportunities for vaccine delivery. The World Health Organization has advised several precautions including social distancing, hand washing and the use of PPE including gloves and face masks for minimizing the spread of SARS-CoV-2 infection. At present, several antiviral therapies previously approved for other infections are being repositioned to study their efficacy against SARS-CoV-2. In addition, some medicines (i.e., remdesivir, chloroquine, hydroxychloroquine) have received emergency use authorisation from the FDA. Plasma therapy has also been authorised for emergency use for the treatment of COVID-19 on a smaller scale. However, no vaccine has been approved so far against this virus. Nevertheless, several potential vaccine targets have been reported, and development of different types of vaccines including DNA, mRNA, viral vector, inactivated, subunit and vaccine-like particles is in process. It is concluded that a suitable candidate delivered through an advanced drug delivery approach would effectively boost the immune system against this coronavirus.

scholarly journals The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2) in Dentistry. Management of Biological Risk in Dental Practice

2020 ◽  
Vol 17 (9) ◽  
pp. 3067 ◽  
Author(s):  
Roberto Lo Giudice
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Clinical Signs ◽  
World Health ◽  
Dental Practice ◽  
Risk Of Infection ◽  
Specific Protocol ◽  
Route Of Transmission ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Spread Of Infection

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a novel coronavirus first identified in Wuhan, China, and the etiological agent of Coronavirus Disease-2019 (COVID-19). This infection spreads mainly through direct contact with Flügge micro droplets or core droplets that remain suspended as aerosol. Moreover, it has been reported that infected subjects, both with and without clinical signs of COVID-19, can transmit the virus. Since the infection typically enters through mouth, nose, and eyes, dentistry is one of the medical practices at highest risk of infection due to the frequent production of aerosol and the constant presence of saliva. The World Health Organization (WHO) has suggested that only emergency/urgent procedures should be performed during the coronavirus outbreak. Considering the virus’ route of transmission, a specific protocol should be applied to reduce the risk of infection in addition to measures that prevent the spread of infection from a patient to another person or medical tools and equipment (cross-infection). This protocol should be implemented by modifying both patient management and clinical practice, introducing particular devices and organizational practices. This paper aims to discuss and suggest the most appropriate procedures in every aspect of dental practice to reduce infection risk.

Sign in / Sign up

Export Citation Format

Share Document